DXCM

• 2026-07-30 share offering or dilution eventfreshOpen filing ↗
  “…273.7 278.7 Total assets $ 6,455.3 $ 6,339.9 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable and…”
  +1 more passage from the same document

  • “…fair value hierarchy: Fair Value Measurements Using (In millions) Level 1 Level 2 Level 3 Total Cash equivalents $ 409.0 $ — $ — $…”
• 2026-07-30 capital return (buybacks/dividends)freshOpen filing ↗
  “…9.7 13.5 21.3 26.3 Selling, general and administrative 26.2 27.8 55.1 46.0 Total share-based compensation expense $ 39.0 $…”
  +1 more passage from the same document

  • “…administrative 26.2 27.8 55.1 46.0 Total share-based compensation expense $ 39.0 $ 45.3 $ 82.3 $ 79.5 As of June 30, 2026,…”
• 2026-05-15 capital return (buybacks/dividends)recentOpen filing ↗
  “…and Adjusted EBITDA Margin is not available without unreasonable effort. The definitions of the non-GAAP financial metrics…”
  +1 more passage from the same document

  • “…Report on Form 8-K filed on February 12, 2026. ITEM 8.01. OTHER EVENTS. On May 14, 2026, Dexcom announced that its Board of…”
• 2026-04-30 share offering or dilution eventrecentOpen filing ↗
  “…285.9 278.7 Total assets $ 6,633.3 $ 6,339.9 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable and…”
  +1 more passage from the same document

  • “…Fair Value Measurements Using (In millions) Level 1 Level 2 Level 3 Total Cash equivalents $ 524.4 $ 13.8 $ — $ 538.2 Debt…”
• 2026-04-30 capital return (buybacks/dividends)recentOpen filing ↗
  “…sales $ 2.8 $ 3.2 Research and development 11.6 12.8 Selling, general and administrative 28.9 18.2 Total share-based compensation…”
  +1 more passage from the same document

  • “…compensation expense $ 43.3 $ 34.2 As of March 31, 2026, unrecognized estimated compensation costs related to RSUs and PSUs…”

Recorded SEC filings in plain language — not advice or a prediction.